Gilead Sciences (GILD)
129.73
+0.55 (0.43%)
Upcoming Events
Latest Headlines
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
June 5, 2026 3:00 AM - BizWire
Gilead and Lakefront complete $1.675 billion Ouro Medicines acquisition
June 4, 2026 4:15 PM - StreetInsider
GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
June 4, 2026 4:15 PM - StreetInsider
Form 4 GILEAD SCIENCES, INC. For: Jun 01 Filed by: O'Day Daniel Patrick
June 2, 2026 6:04 PM - SEC Filing
GILD reports positive results for Livdelzi in PBC patients with mild ALP elevation
June 2, 2026 8:30 AM - StreetInsider
Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
June 2, 2026 8:30 AM - BizWire
Form 144 GILEAD SCIENCES, INC. Filed by: O'Day Daniel Patrick
June 1, 2026 4:45 PM - SEC Filing
RBC Capital Reiterates Sector Perform Rating on Gilead Sciences (GILD)
June 1, 2026 7:47 AM - StreetInsider
Gilead's Livdelzi shows sustained liver marker improvement in PBC study
May 27, 2026 2:00 AM - StreetInsider
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)
May 27, 2026 2:00 AM - BizWire
FDA approves Gilead's Hepcludex as first HDV treatment in U.S.
May 22, 2026 2:00 PM - StreetInsider
FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
May 22, 2026 2:00 PM - BizWire
FDA Approves Hepcludex injection to treat chronic Hepatitis Delta virus infection in adults w/o Cirrhosis or w/ compensated Cirrhosis
May 22, 2026 1:42 PM - StreetInsider
China holds roundtable with over 50 foreign pharmaceutical firms
May 22, 2026 9:54 AM - StreetInsider
Gilead receives EU panel backing for Trodelvy in breast cancer treatment
May 22, 2026 7:47 AM - StreetInsider
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
May 22, 2026 7:47 AM - BizWire
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
May 21, 2026 5:00 PM - BizWire
Gilead Sciences completes $3.15 billion Tubulis acquisition
May 21, 2026 9:30 AM - StreetInsider
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
May 21, 2026 9:30 AM - BizWire
Gilead Sciences extends WHO partnership to fight visceral leishmaniasis
May 21, 2026 5:55 AM - StreetInsider
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
May 21, 2026 3:30 AM - BizWire
Gilead Sciences issues $3 billion in senior notes across four tranches
May 20, 2026 4:19 PM - StreetInsider
Form 8-K GILEAD SCIENCES, INC. For: May 14
May 20, 2026 4:16 PM - SEC Filing
Maxim Group Upgrades Gilead Sciences (GILD) to Buy
May 20, 2026 8:09 AM - StreetInsider
Form 4 GILEAD SCIENCES, INC. For: May 15 Filed by: Dickinson Andrew D
May 18, 2026 5:51 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: May 15 Filed by: Mercier Johanna
May 18, 2026 5:46 PM - SEC Filing
Form 424B5 GILEAD SCIENCES, INC.
May 18, 2026 4:26 PM - SEC Filing
Form 144 GILEAD SCIENCES, INC. Filed by: Mercier Johanna
May 15, 2026 4:14 PM - SEC Filing
Form 144 GILEAD SCIENCES, INC. Filed by: Dickinson Andrew D
May 15, 2026 4:12 PM - SEC Filing
Gilead Prices $3 Billion of Senior Unsecured Notes
May 14, 2026 9:21 PM - BizWire
Form FWP GILEAD SCIENCES, INC. Filed by: GILEAD SCIENCES, INC.
May 14, 2026 5:12 PM - SEC Filing
Form 424B5 GILEAD SCIENCES, INC.
May 14, 2026 8:46 AM - SEC Filing
Gilead to present 29 abstracts on liver disease treatments at EASL 2026
May 13, 2026 8:30 AM - StreetInsider
Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026
May 13, 2026 8:30 AM - BizWire
RBC Capital on Gilead Sciences (GILD): 'What To Look For In Upcoming UC Readout'
May 11, 2026 8:42 AM - StreetInsider
Gilead Sciences (GILD) PT Lowered to $168 at Morgan Stanley
May 11, 2026 8:27 AM - StreetInsider
Form 13F-HR GILEAD SCIENCES, INC. For: Mar 31
May 8, 2026 5:01 PM - SEC Filing
Gilead Sciences (GILD) PT Lowered to $122 at RBC Capital
May 8, 2026 7:30 AM - StreetInsider
Gilead Sciences (GILD) PT Raised to $157 at Truist Securities
May 8, 2026 7:19 AM - StreetInsider
Gilead Sciences (GILD) PT Lowered to $168 at Morgan Stanley
May 8, 2026 6:18 AM - StreetInsider
Stocks expected to have increasing option volume: GILD OPEN SYNA ARLO HUBS FROG SG WEN FIS MXK MELI MCHP RILY RNG QCOM SERV LOCO YELP REAL IREN GSAT MSI
May 8, 2026 4:42 AM - StreetInsider
Form S-8 GILEAD SCIENCES, INC.
May 7, 2026 5:14 PM - SEC Filing
Form 10-Q GILEAD SCIENCES, INC. For: Mar 31
May 7, 2026 5:12 PM - SEC Filing
Gilead Sciences (GILD) Tops Q1 EPS by 13c, Beats on Revenue; Offers FY26 Guidance
May 7, 2026 4:07 PM - StreetInsider
Form 8-K GILEAD SCIENCES, INC. For: May 07
May 7, 2026 4:03 PM - SEC Filing
Gilead Sciences Announces First Quarter Financial Results
May 7, 2026 4:01 PM - BizWire
Gilead Sciences (GILD) call put ratio 1 call to 1.3 puts with a focus on May 8 weekly 135 calls into quarter results
May 7, 2026 10:38 AM - StreetInsider
Gilead Sciences (GILD) call put ratio 1.9 calls to 1 put with a focus on June options into quarter results
May 6, 2026 11:08 AM - StreetInsider
Form 4 GILEAD SCIENCES, INC. For: Apr 30 Filed by: Bluestone Jeffrey
May 4, 2026 4:40 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Apr 30 Filed by: BARTON JACQUELINE K
May 4, 2026 4:37 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Apr 30 Filed by: Horning Sandra
May 4, 2026 4:33 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Apr 30 Filed by: LOVE TED W
May 4, 2026 4:29 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Apr 30 Filed by: Rodriguez Javier
May 4, 2026 4:25 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Apr 30 Filed by: WELTERS ANTHONY
May 4, 2026 4:23 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Apr 30 Filed by: MANWANI HARISH
May 4, 2026 4:21 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Apr 30 Filed by: Kramer Kelly A.
May 4, 2026 4:19 PM - SEC Filing
Form 8-K GILEAD SCIENCES, INC. For: Apr 30
May 4, 2026 4:07 PM - SEC Filing
Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences
May 1, 2026 6:00 AM - BizWire
Form SCHEDULE 13G GILEAD SCIENCES, INC. Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 29, 2026 6:42 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Apr 28 Filed by: O'Day Daniel Patrick
April 29, 2026 5:54 PM - SEC Filing
FDA grants priority review to Gilead's HIV treatment combination
April 29, 2026 8:30 AM - StreetInsider
U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
April 29, 2026 8:30 AM - BizWire
Form 144 GILEAD SCIENCES, INC. Filed by: O'Day Daniel Patrick
April 28, 2026 4:13 PM - SEC Filing
Form 8-K GILEAD SCIENCES, INC. For: Apr 28
April 28, 2026 8:57 AM - SEC Filing
Gilead Sciences completes $7.8 billion Arcellx acquisition
April 28, 2026 8:45 AM - StreetInsider
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
April 28, 2026 8:45 AM - BizWire
Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
April 22, 2026 4:05 PM - BizWire
Gilead extends Arcellx tender offer after clearing regulatory hurdles
April 17, 2026 8:30 AM - StreetInsider
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
April 17, 2026 8:30 AM - BizWire
Form 4 GILEAD SCIENCES, INC. For: Apr 15 Filed by: Dickinson Andrew D
April 16, 2026 6:42 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Apr 15 Filed by: Mercier Johanna
April 16, 2026 6:40 PM - SEC Filing
RBC Capital Reiterates Sector Perform Rating on Gilead Sciences (GILD), flags Yeztugo risks
April 16, 2026 6:33 AM - StreetInsider
Form 144 GILEAD SCIENCES, INC. Filed by: Mercier Johanna
April 15, 2026 4:13 PM - SEC Filing
Form 144 GILEAD SCIENCES, INC. Filed by: Dickinson Andrew D
April 15, 2026 4:08 PM - SEC Filing
PEPFAR and Global Fund expand lenacapavir access to 1 million more people
April 14, 2026 12:03 PM - StreetInsider
PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access
April 14, 2026 12:00 PM - BizWire
Bernstein on US Pharma and Biotech: Who might buy whom?
April 13, 2026 5:52 AM - StreetInsider
Gilead Sciences (GILD) PT Raised to $175 at Morgan Stanley
April 10, 2026 8:15 AM - StreetInsider
Tempus expands multi-year collaboration with Gilead for oncology research
April 9, 2026 8:30 AM - StreetInsider
Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE
April 9, 2026 8:30 AM - BizWire
Gilead exercises option for Kymera's cancer drug candidate KT-200
April 9, 2026 7:03 AM - StreetInsider
TD Cowen on Gilead Sciences (GILD): 'We Are Excited By Gilead's Recent String Of Deals'
April 8, 2026 9:02 AM - StreetInsider
BMO Capital Reiterates Outperform Rating on Gilead Sciences (GILD)
April 8, 2026 8:52 AM - StreetInsider
Gilead Sciences (GILD) Reiterated at Overweight by Cantor Fitzgerald on Likely Positive Call
April 8, 2026 7:45 AM - StreetInsider
Gilead Sciences (GILD) PT Raised to $155 at Truist Securities
April 8, 2026 6:06 AM - StreetInsider
Oppenheimer on Gilead Sciences (GILD): 'Story Near-Term Remains Squarely HIV Focused'
April 8, 2026 6:01 AM - StreetInsider
Gilead to acquire Tubulis for up to $5 billion to expand cancer pipeline
April 7, 2026 9:33 AM - StreetInsider
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
April 7, 2026 9:32 AM - BizWire
Gilead Sciences (GILD) PT Raised to $123 at RBC Capital
April 7, 2026 8:59 AM - StreetInsider
Gilead Sciences to acquire Tubulis for up to $5 billion
April 7, 2026 8:32 AM - StreetInsider
Gilead To Buy Tubulis For $3.15B Cash, Up To $1.85B Contingent - Bloomberg
April 7, 2026 8:00 AM - StreetInsider
Gilead Sciences (GILD) Reiterated at Overweight by Cantor Fitzgerald on Yeztugo TRx Gains
April 6, 2026 7:39 AM - StreetInsider
Gilead extends Arcellx tender offer deadline to April 24
April 1, 2026 4:13 PM - StreetInsider
Gilead Extends Tender Offer to Acquire Arcellx
April 1, 2026 4:13 PM - BizWire
UBS Reiterates Buy Rating on Gilead Sciences (GILD)
March 31, 2026 9:32 AM - StreetInsider
Galapagos enters partnership with Gilead for autoimmune drug development
March 31, 2026 6:19 AM - StreetInsider
Form 4 GILEAD SCIENCES, INC. For: Mar 27 Filed by: O'Day Daniel Patrick
March 30, 2026 6:02 PM - SEC Filing
Form 144 GILEAD SCIENCES, INC. Filed by: O'Day Daniel Patrick
March 27, 2026 4:03 PM - SEC Filing
Deutsche Bank stays Buy rated on Gilead Sciences (GILD) amid weekly scripts
March 27, 2026 11:27 AM - StreetInsider
Form SCHEDULE 13G/A GILEAD SCIENCES, INC. Filed by: VANGUARD GROUP INC
March 26, 2026 6:40 PM - SEC Filing
Clear Street Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)
March 24, 2026 3:02 PM - StreetInsider
Bernstein on Gilead Sciences (GILD) Amid Ouro Acquisition
March 24, 2026 8:13 AM - StreetInsider
Goldman Sachs: 'we expect GILD to continue to engage in strategic BD'
March 24, 2026 6:36 AM - StreetInsider
Truist on Gilead Sciences (GILD): 'old Rush: $2B Deal for Ouro Adds I&I Strength with BCMAxCD3 TCE in Orphan Autoimmune Indications
March 24, 2026 5:23 AM - StreetInsider
Gilead to buy Ouro Medicines for up to $2.2 billion
March 23, 2026 6:30 PM - StreetInsider
Gilead Sciences to acquire Ouro Medicines for up to $2.2 billion
March 23, 2026 6:15 PM - StreetInsider
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
March 23, 2026 6:15 PM - BizWire
Gilead nears up to $2bn deal for autoimmune biotech Ouro Medicines - FT
March 23, 2026 12:34 PM - StreetInsider
Form ARS GILEAD SCIENCES, INC. For: Dec 31
March 20, 2026 4:02 PM - SEC Filing
Form DEF 14A GILEAD SCIENCES, INC. For: Apr 30
March 20, 2026 4:02 PM - SEC Filing
Form DEFA14A GILEAD SCIENCES, INC.
March 20, 2026 4:01 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Mar 16 Filed by: Mercier Johanna
March 17, 2026 6:56 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Mar 16 Filed by: Dickinson Andrew D
March 17, 2026 6:14 PM - SEC Filing
Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD)
March 17, 2026 7:36 AM - StreetInsider
Form 144 GILEAD SCIENCES, INC. Filed by: Mercier Johanna
March 16, 2026 4:07 PM - SEC Filing
Form 144 GILEAD SCIENCES, INC. Filed by: Dickinson Andrew D
March 16, 2026 4:06 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: Dickinson Andrew D
March 12, 2026 4:46 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: Mercier Johanna
March 12, 2026 4:42 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: Cain Wettan Keeley M
March 12, 2026 4:40 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: Burkhart Erin
March 12, 2026 4:38 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: O'Day Daniel Patrick
March 12, 2026 4:26 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: Berger Dietmar
March 12, 2026 4:23 PM - SEC Filing
Jefferies Starts Vertex (VRTX) at Buy
March 10, 2026 5:37 AM - StreetInsider
Jefferies Starts Gilead Sciences (GILD) at Buy
March 10, 2026 5:37 AM - StreetInsider
Jefferies Starts Amgen (AMGN) at Hold
March 10, 2026 5:37 AM - StreetInsider
Full Article List
